Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma

por Nishioka, Naoya, Kaneko, Yoshiko, Yamada, Tadaaki, Okura, Naoko, Hirai, Soichi, Takayama, Koichi
Publicado 2018

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutat...

por Sawada, Ryo, Nishioka, Naoya, Kim, Young Hak, Kiyomi, Fumiaki, Uchino, Junji, Takayama, Koichi
Publicado 2023

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with l...

por Nishioka, Naoya, Yamada, Tadaaki, Harita, Sachi, Hirai, Soichi, Katayama, Yuki, Nakano, Takayuki, Okura, Naoko, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Publicado 2018

The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status

por Kaneko, Yoshiko, Mouri, Takako, Seto, Yurie, Nishioka, Naoya, Yoshimura, Akihiro, Yamamoto, Chie, Harita, Sachi, Chihara, Yusuke, Tamiya, Nobuyo, Yamada, Tadaaki, Uchino, Junji, Takayama, Koichi
Publicado 2020

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

por Yoshimura, Akihiro, Yamada, Tadaaki, Okura, Naoko, Takeda, Takayuki, Furutani, Wataru, Kubota, Yutaka, Shiotsu, Shinsuke, Hiranuma, Osamu, Nishioka, Naoya, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Publicado 2018

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

por Nishioka, Naoya, Uchino, Junji, Hirai, Soichi, Katayama, Yuki, Yoshimura, Akihiro, Okura, Naoko, Tanimura, Keiko, Harita, Sachi, Imabayashi, Tatsuya, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Yamada, Tadaaki, Takayama, Koichi
Publicado 2019

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

por Katayama, Yuki, Yamada, Tadaaki, Tokuda, Shinsaku, Okura, Naoko, Nishioka, Naoya, Morimoto, Kenji, Tanimura, Keiko, Morimoto, Yoshie, Iwasaku, Masahiro, Horinaka, Mano, Sakai, Toshiyuki, Kita, Kenji, Yano, Seiji, Takayama, Koichi
Publicado 2022

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer

por Nishioka, Naoya, Naito, Tateaki, Notsu, Akifumi, Mori, Keita, Kodama, Hiroaki, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Takayama, Koichi, Takahashi, Toshiaki
Publicado 2020

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation

por Kodama, Hiroaki, Kenmotsu, Hirotsugu, Kawabata, Takanori, Notsu, Akifumi, Yabe, Michitoshi, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Takahashi, Toshiaki
Publicado 2021

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

por Nishimura, Ari, Ono, Akira, Wakuda, Kazushige, Kawabata, Takanori, Yabe, Michitoshi, Miyawaki, Taichi, Miyawaki, Eriko, Kodama, Hiroaki, Nishioka, Naoya, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Takahashi, Toshiaki
Publicado 2021

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

por Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Publicado 2021

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer

por Nishioka, Naoya, Naito, Tateaki, Miyawaki, Taichi, Yabe, Michitoshi, Doshita, Kosei, Kodama, Hiroaki, Miyawaki, Eriko, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Takayama, Koichi, Takahashi, Toshiaki
Publicado 2022

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

por Miyawaki, Taichi, Naito, Tateaki, Kodama, Akihro, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Notsu, Akifumi, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Publicado 2020

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

por Miyawaki, Taichi, Kenmotsu, Hirotsugu, Doshita, Kosei, Kodama, Hiroaki, Nishioka, Naoya, Iida, Yuko, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Publicado 2022

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Thera...

por Doshita, Kosei, Tabuchi, Yuya, Kenmotsu, Hirotsugu, Omori, Shota, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, Takahashi, Toshiaki
Publicado 2022

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

por Miyawaki, Taichi, Naito, Tateaki, Doshita, Kosei, Kodama, Hiroaki, Mori, Mikiko, Nishioka, Naoya, Iida, Yuko, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Publicado 2022

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

por Yoshimura, Akihiro, Yamada, Tadaaki, Okuma, Yusuke, Fukuda, Akito, Watanabe, Satoshi, Nishioka, Naoya, Takeda, Takayuki, Chihara, Yusuke, Takemoto, Shinnosuke, Harada, Taishi, Hiranuma, Osamu, Shirai, Yukina, Nishiyama, Akihiro, Yano, Seiji, Goto, Yasuhiro, Shiotsu, Shinsuke, Kunimasa, Kei, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Kenmotsu, Hirotsugu, Takahashi, Toshiaki, Takayama, Koichi
Publicado 2021

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

por Yoshimura, Akihiro, Yamada, Tadaaki, Serizawa, Masakuni, Uehara, Hisanori, Tanimura, Keiko, Okuma, Yusuke, Fukuda, Akito, Watanabe, Satoshi, Nishioka, Naoya, Takeda, Takayuki, Chihara, Yusuke, Takemoto, Shinnosuke, Harada, Taishi, Hiranuma, Osamu, Shirai, Yukina, Shukuya, Takehito, Nishiyama, Akihiro, Goto, Yasuhiro, Shiotsu, Shinsuke, Kunimasa, Kei, Morimoto, Kenji, Katayama, Yuki, Suda, Kenichi, Mitsudomi, Tetsuya, Yano, Seiji, Kenmotsu, Hirotsugu, Takahashi, Toshiaki, Takayama, Koichi
Publicado 2022